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Abstract: Infective endocarditis (IE) is a rare condition which is 
associated with considerable morbidity and mortality. Almost 100 years 
ago, the links between endocarditis and procedures, particularly dental 
procedures, were postulated. Over 50 years ago the first guidelines 
recommending antibiotic prophylaxis (AP), with the aim of preventing IE 
developing after procedures, were proposed. However, there has only ever 
been circumstantial evidence in humans that AP prevents IE. The rarity of 
IE has made a randomised controlled clinical trial impractical to date. 
This article outlines the history of AP and reviews the evidence base for 
the use of AP to prevent IE. 
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Abstract 
 
Infective endocarditis (IE) is a rare condition which is associated with considerable morbidity 
and mortality. Almost 100 years ago, the links between endocarditis and procedures, 
particularly dental procedures, were postulated. Over 50 years ago the first guidelines 
recommending antibiotic prophylaxis (AP), with the aim of preventing IE developing after 
procedures, were proposed. However, there has only ever been circumstantial evidence in 
humans that AP prevents IE. The rarity of IE has made a randomised controlled clinical trial 
impractical to date. This article outlines the history of AP and reviews the evidence base for 
the use of AP to prevent IE.   
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Infective Endocarditis 
 
Infective endocarditis is a rare infection, affecting around 5-10 people per 100,000 per 
annum.[1-3] It has a high morbidity, typically requiring prolonged courses of antibiotics and 
often valve replacement surgery. Mortality is also high, not only in hospital, but also in the 
first year after discharge. Consequently, this is a disease that is important to prevent, and 
for many years antibiotic prophylaxis prior to invasive, particularly dental, procedures has 
been normal practice across the world.  
 
In Japan, a recent survey of 513 cases has described the epidemiology of the disease 
between 2007 and 2009.[4] The most common age of presentation was 61-80 years. 62% 
were men. 11% died. 69% of cases had known underlying heart disease; 36% of cases were 
related to native valve disease. Periodontitis / tooth decay was noted in 25%, and dental 
treatment was identified as a predisposing factor in 16% of cases, although the timing of 
intervention was not given. Approximately 1/3
rd
 had AP, but it was unclear in another 1/3
rd
 
whether AP was used or not. Oral viridans group Streptococci (OVGS) were identified as the 
causative organism in 26% of cases. This is a relatively high percentage compared with other 
contemporary studies,[5, 6] ĂŶĚŝƐĂŵŽƌĞ ?ĐůĂƐƐŝĐĂů ?ƉŝĐƚƵƌĞŽĨ/ ?[7] 
 
This article will set out the history behind the development of AP as a potential preventative 
measure, and the evidence behind it. It will become clear that the evidence is not robust, 
and that practice reflects a consensus opinion, rather than strong evidence.  
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The Origins of Antibiotic Prophylaxis 
 
In 1923 Lewis and Grant first suggested that infective endocarditis (IE) might be caused by bacteria 
released into the circulation during a dental procedure.[8] In 1935, Okell and Elliot confirmed that 
this was the case, isolating Streptococcus viridans in blood cultures in 84/138 (61%) of individuals.[9] 
Shortly after this, in 1941, the first recorded use of antibiotic prophylaxis (AP) took place.[10] In 
1955 the American Heart Association (AHA) issued the first guidelines, ƐƚĂƚŝŶŐ ƚŚĂƚ  ?/ƚ ŝƐ ŐŽŽĚ
medical and dental practice to protect patients with rheumatic or congenital heart disease by 
ƉƌŽƉŚǇůĂĐƚŝĐŵĞĂƐƵƌĞƐ ? ?[11]  
 
But, whereas many guidelines in other aspects of cardiology are clearly  ?evidence based ?, guidelines 
for AP to prevent IE have largely been based on consensus. In 1962, Hook and Kaye stated  ?dŚĞƌĞŝƐ
ŶŽƉƌŽŽĨƚŚĂƚƉƌŽƉŚǇůĂǆŝƐǁŝƚŚĂŶƚŝďŝŽƚŝĐƐŝƐĞĨĨĞĐƚŝǀĞ ?,ŽǁĞǀĞƌ ?ƚŚĞƵƐĞŽĨƉƌŽƉŚǇůĂĐƚŝĐĂŶƚŝďŝŽƚŝĐƐ
appears to be a reasonable approach to the problem and the consensus of opinion strongly supports 
ƚŚĞƵƐĞŽĨĂŶƚŝďŝŽƚŝĐƐŝŶƚŚŝƐƐŝƚƵĂƚŝŽŶ ?.[12] 
 
Since the original AHA guidelines, there have been many revisions and, furthermore, guidelines have 
been developed around the world to suit local populations. There is now considerable variation 
between countries as to what is recommended.  
 
In Japan, patients considered to be at high risk, such as those with previous IE or a prosthetic valve, 
as well as patients at moderate risk, such as acquired valve disease or hypertrophic cardiomyopathy, 
are currently recommended to have AP.[13] In Europe and America, patients considered to be at 
high risk only are recommended to have AP prior to dental procedures.[14, 15] At the opposite 
extreme to Japan, UK guidelines recommend against AP.[16] This situation reflects the uncertainty 
as to whether AP is effective or not. 
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The Evidence for Antibiotic Prophylaxis 
 
Antibiotic prophylaxis was initially based upon the assumption that giving antibiotics to individuals 
susceptible to IE, prior to a procedure known to release bacteria into the bloodstream, would reduce 
the risk of developing IE subsequently.  
 
A number of different types of experiment have been performed to try to ascertain the efficacy of 
AP: 
 
1. Animal studies. 
2. The impact of antibiotics prior to dental, or other, procedures on bacteraemias in humans. 
3. Case control and cohort studies. 
4. Studies using administrative databases before and after changes to guidelines. 
5. Studies using administrative databases to determine the impact of prophylaxis prior to 
procedures in at-risk individuals.  
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Animal Studies 
 
David Durack and colleagues published the first animal model studies demonstrating that infective 
endocarditis might be prevented with prophylactic antibiotics in the early 1970s. In 1973, Durack 
and Petersdorf described an animal model of endocarditis. In this model, a polyethylene catheter 
was passed into the right side of the heart via the jugular vein, or the left side via the carotid artery 
and secured in place. After 1-3 days 10
8
 colony-forming units of Streptococcus viridans was given 
intravenously. It was reported that this procedure produced endocarditis in every animal. To 
determine the efficacy of antibiotic prophylaxis, antibiotics were given orally, intramuscularly or 
intravenously, depending on the antibiotic. Procaine penicillin was successful in preventing 
Streptococcal endocarditis.[17] Other groups soon replicated the results. However, there has never 
been, to our knowledge, a systematic review of these studies.  
 
The animal studies are often dismissed as being unrealistic models, both because of the presence of 
the indwelling catheter and the very large number of bacteria used to produce the bacteraemia. 
However, as medical knowledge progresses in a Bayesian fashion, the fact that these studies have 
been positive means that studies purporting to show an effect in humans are more likely to be true 
than would be the case If AP had not been shown to work in animal models; therefore, these results 
should not be overlooked.  
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The Impact of Antibiotic Prophylaxis Prior to Dental or Other Procedures on Bacteraemias in 
Humans 
 
The impact of antibiotic prophylaxis prior to dental or other procedures on the development of 
bacteraemias in humans has been extensively studied. However, the effects of antibiotics are 
controversial, with some studies reporting a positive effect, and others not. More recent studies, 
carefully performed, have demonstrated that amoxicillin can reduce the frequency of bacteraemias, 
but that it is not 100% effective.[18, 19] Importantly, a number of more recent studies have 
suggested that clindamycin may not be particularly effective.[19, 20] 
 
What has also become clear is that everyday activities, such as tooth-brushing, dental flossing and 
chewing,[18, 21-23] can also release bacteria into the bloodstream, although the frequency of 
bacteraemia is less than after a dental extraction and the duration less, suggesting that the 
magnitude of bacteraemia is also less. The frequency and magnitude of bacteraemia caused by daily 
activities is also likely to be influenced by the state of oral hygiene and presence of periodontal 
disease. Indeed, individuals with markers of poor oral hygiene are 4-8 times more likely to develop a 
bacteraemia with organisms that can cause IE following tooth brushing than those with better 
standards of oral hygiene.[24] 
 
It has therefore been cogently argued that as dental interventions are relatively rare, whereas tooth 
brushing is common, it is illogical to give antibiotic prophylaxis, as there is no sense in preventing 
bacteraemia once or perhaps twice a year, when it is happening on a daily basis in between times. It 
is hard to argue with this stance, however, there are no studies which have reliably quantified the 
magnitude of bacteraemias after extractions in comparison with tooth-brushing or other similar 
activities, and it is unknown as to whether or not there is a threshold below which the number of 
bacteria present are unable to cause endocarditis. Furthermore, the argument does not exclude the 
possibility that AP may prevent some cases of IE.  
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Case Control and Cohort Studies 
 
Case control and cohort studies have been undertaken in an effort to understand whether dental 
procedures can cause IE and also whether AP might be effective. 
 
Horstkotte in 1986 compared 229 patients with prosthetic heart valves in whom 287 procedures 
were performed and who had AP, with 304 patients with prosthetic heart valves in whom 390 
similar interventions were performed and who did not have AP.[25] In the first group no patient 
developed IE. In the second group, 6 developed IE within 14 days. This study has been cited 
frequently as evidence that AP works. However, due to the limited information contained within the 
study, more recent reviews have discounted it.[26]  
 
Imperiale and Horowitz published a very small case control study in 1990.[27] They enrolled 8 
patients with ³high-risk´ lesions who had IE for the first time on a native valve within 12 weeks of a 
dental procedure. They were matched with 3 patients who had also undergone a dental procedure 
and who had a similar valve lesion and age. AP was used by 1/8 patients and by 15/24 controls. They 
concluded that AP offered protection from IE. It is hard to draw conclusions from such a small study.  
 
Van Der Meer et al. published two linked studies from the Netherlands in 1992. The first was an 
observational study of 427 cases with late prosthetic or native valve infective endocarditis.[28] 275 
were eligible for AP with previously known valve disease or a prosthetic valve. Only 31 had 
undergone any invasive procedure within the previous 30 days. 8 of these had had AP. This study 
suggested that medical and dental procedures were responsible for only a small proportion of cases 
of IE and also that AP is inconsistently applied in the real world. The second study was a case-control 
study that examined the efficacy of antibiotic prophylaxis to prevent IE in patients with native valve 
disease.[29] 48 patients who developed IE within 180 days of a medical or dental procedure 
requiring AP were compared with 200 age-matched controls who had a relevant procedure but did 
not develop IE. Most patients and controls had undergone a dental procedure. AP was given to 8/48 
cases and 26/200 controls. It was estimated that AP, when given to patients who had not had IE 
before, reduced the risk of developing IE within 30 days by 49%. However, it was noted, in the 
discussion, that 9/10 patients who developed IE did not develop IE as a consequence of a procedure, 
meaning that AP would only prevent a minority of cases.  
 
Lacassin et al compared 171 cases of IE with 171 controls matched for age, sex and underlying heart 
condition.[30] They found no increased risk of IE for dental procedures as a whole, although scaling 
and root canal treatment came close to reaching conventional levels of significance. 48 subjects with 
known heart disease underwent a dental procedure (26 cases and 22 controls). 6 cases and 6 
controls received AP. For Streptococcus viridans and those with negative blood cultures 3/18 cases 
received AP whereas 6/22 controls did. Although there was some evidence of protection therefore, 
this did not reach statistical significance.  
 
Strom et al. published a case-control study in 1998. Patients with community acquired IE not 
associated with intravenous drug use were compared with healthy controls matched for age, sex 
and neighbourhood of residence. It was concluded that dental procedures were no more frequent in 
patients with IE than controls and that AP would be unlikely to prevent many cases, even if 100% 
effective.[31]  
 
Taken together, these studies do not exclude the possibility that AP is effective, but the numbers are 
small, and precise definitions of cases, procedures and risk factors limited. What is clear is that AP 
will only prevent a small proportion of IE cases. 
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Studies Using Administrative Databases Before and After Changes to Guidelines 
 
In recent times data collected at a national level has become available for analysis and has enabled 
researchers to assess the impact of guideline changes on the rates of infective endocarditis. We have 
recently reviewed this literature,[32] and further studies have been published since. The data is 
complex to interpret and conflicting in its conclusions.  
 
It is first instructive to review the guideline changes that have been studied.  
 
In 2007, the American Heart Association released new guidelines for antibiotic prophylaxis.[33] The 
previous iteration in 1997[34] had recommended antibiotic prophylaxis for patients at high risk, 
including those with prosthetic valves, previous bacterial endocarditis, complex cyanotic congenital 
heart disease and surgical shunts used to correct complex congenital heart disease. They also 
recommended antibiotic prophylaxis for patients deemed to be at moderate risk of developing 
endocarditis. These included patients with congenital heart disease, acquired valvular heart disease 
and hypertrophic cardiomyopathy. The 2007 guidance restricted antibiotic prophylaxis to those at 
high risk of developing or suffering an adverse outcome from IE. They also modified the criteria 
slightly, with more detail regarding congenital heart disease, and including patients who had 
undergone cardiac transplantation and had evidence of valve disease in the high-risk cohort. 
 
The impact of this guideline change has been examined in both the United States and also Canada. 
Bikdeli et al. looked at Medicare beneficiaries in the United States.[35] Medicare patients are those 
aged greater than or equal to 65 years only. A total of 52,145 patients were hospitalised with a 
principal diagnosis of IE during the study period. They noted that the rates of infective endocarditis 
were falling, and that the fall appeared to accelerate after the guideline change. 
 
Pant et al. used the Nationwide Inpatient Sample database.[36] This is a representative sample of all 
patients looked after in the US, and comprises about 20% of the population. In this study, the rates 
of infective endocarditis were rising, but there was no acceleration in the rate of rise after the 
guideline change. However, they reported that the incidence of endocarditis caused by all 
Streptococci (not just OVGS) did accelerate after the guideline change. 
 
De Simone et al. also looked at the Nationwide Inpatient Sample, but they used different codes to 
Pant to identify patients more likely to have OVGS.[37] In contrast to the previous study, they found 
that the rates of infective endocarditis likely to be due to OVGS were falling after the guideline 
change. 
 
Mackie et al. looked at the changes in Canada, except for patients in Quebec and the Northern 
Territories.[38] They noted a gradual rise in the of cases of infective endocarditis. The rate of rise did 
not change after the new guidelines were introduced. However, there was a trend that endocarditis 
cases likely to be due to OVGS were rising following the guideline change, whereas before there was 
a clear decline in the number of cases.[39] 
 
Most recently, Toyoda et al. published one of the most detailed studies looking at the impact of the 
2007 guidelines in the US.[6] They looked at trends in California and New York only. They noted no 
change in the number of cases of OVGS endocarditis, and a slight fall in the total number of cases of 
endocarditis since the guideline change.  
 
A slightly different study by DeSimone looked at antibiotic prescribing in Olmstead county before 
and after the guideline change.[40] One of the criticisms that has been levelled at the studies above 
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is that no assessment of antibiotic prescribing was made, and therefore the impact of the guideline 
change on clinical practice was unclear. This study demonstrated that the percentage of patients at 
moderate risk given AP fell dramatically and significantly after the introduction of the guidelines, 
from 64.6% to 8.6%. However, it cannot be assumed that these results can be generalised across the 
United States.  
 
The European Society of Cardiology updated its 2004 guidelines[41] for the prevention of IE in 
2009.[42] They adopted a similar approach to the Americans, moving from advising that patients at 
moderate or high risk should have AP, to just recommending it for patients at high risk.   
 
Van den Brink et al. looked at the incidence of IE in the Netherlands before and after the ESC 
guideline change in 2009 using their National Healthcare Insurance Database.[43] There was a 
steady growth in the number of cases of IE over the time period, with no change in the rate of rise 
after 2009. However, as a sub-analysis, they also performed an in-depth review of all patients 
admitted with IE in 3 district general hospitals. They noted that there was a significant increase in 
the proportion of cases due to Streptococci after 2009 when compared with the time period before, 
from 31.1% to 53.2% (p=0.0031). 
 
Keller et al. used Nationwide Inpatient Statistics to look at the change in IE incidence in Germany 
between 2005 and 2014.[3] These cover about 25% of the patients in Germany. In contrast to the 
van den Brink study, they demonstrated a significant rate of rise in the number of cases of IE after 
2009. When they looked in more detail at cases due to Streptococci, however, there was no change 
in the rate of rise.  
 
In March 2008 the National Institute for Health and Care Excellence published their 
recommendations regarding the use of AP in England.[44] To everyone¶s surprise they 
recommended that AP should no longer be used, citing the lack of strong evidence for its efficacy, 
and expressing concerns about potential side effects from the use of AP, the potential development 
of antibiotic resistance, and the cost. The UK went from prescribing AP widely to patients at 
moderate and high risk of IE to not using AP at all.[45] 
 
Our group have investigated the impact of this change, publishing articles in the BMJ in 2011[46] and 
the Lancet in 2015 using Hospital Episode Statistics.[2] We have demonstrated that since the 
introduction of the NICE guidelines there has been a dramatic fall in antibiotic prescribing, from an 
average of 10,900 prescriptions per month before the guidelines were introduced, to 2,236 
prescriptions per month (p<0.0001). We also showed that, starting in March 2008, the number of 
cases of infective endocarditis increased significantly above the projected historical trend, by 0.11 
cases per 10 million people per month (95% CI 0.05-0.16, p<0.0001). To date, this is the only study to 
have looked at the impact of stopping AP for those at high-risk of IE as well as those at moderate-
risk. It is also the only study to have looked at the effect of guideline change on AP prescribing as 
well as incidence of IE.  
 
How to understand the variation in the conclusions of these studies? The first thing to appreciate is 
that the coding used between the various studies to identify cases of endocarditis is different (Table 
1). Furthermore, only one study  ? the recent study published by Toyoda et al.[6]  ? published data on 
the sensitivity and specificity of the coding used in identifying cases of IE. Even this study did not 
confirm that coding has not changed over time. It is reasonable to hypothesise that coding has 
improved over time. Coding is used to determine funding in a number of countries and finance is 
becoming ever more important.  
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It is also important to realise that there are no ICD-9 or 10 codes that identify OVGS specifically. 
Again, codes used to identify cases of Streptococcal, and particularly OVGS endocarditis vary 
markedly between studies, making comparison difficult (Table 2). 
 
Finally, these studies are observational and cannot explain the changes observed. Over the time 
periods studied there have been many changes, other than to guidelines for AP. Some of these, such 
as a growing and ageing society, better diagnostic techniques and the increasing use of new medical 
technologies such as percutaneous prosthetic valve insertion, may naturally tend to increase rates of 
endocarditis. Other changes, such as a focus on practices to reduce healthcare associated infection, 
most notably espoused by such organisations as the Institute for Healthcare Improvement, may tend 
to reduce rates.  
 
In conclusion, despite earlier hopes, taken together, these studies have not answered the question 
as to whether antibiotic prophylaxis is effective.  
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Studies Using Administrative Databases to Determine the Impact of Prophylaxis Prior to 
Procedures in At-Risk Individuals  
 
It is clear from some of the cohort studies that AP is given inconsistently, i.e. not all patients 
recommended for AP by guidelines are given AP in real life. By combining prescribing data, dental 
procedure data, and hospital record data it should be possible to observe whether AP is effective or 
not. It does require quite sophisticated administrative systems, and often requires particular 
permissions to allow the synthesis of data across databases to avoid transgressing data protection 
regulations.  
 
The first of these such studies, and we are aware of at least one other which is in progress, has 
recently been accepted for publication. Tubiana et al.[47] identified 138,076 individuals with a 
prosthetic valve in France, and followed them for a total of 285,034 person-years. 69,303 individuals 
underwent 103,463 dental procedures which had an indication for AP. However, AP was given in 
only 50.5% of these cases. A total 267 patients developed IE likely to have been caused by OVGS 
during the follow-up period. Of these, a total of 4 patients developed IE within 3 months of an 
invasive dental procedure after receiving AP, whereas 10 who did not receive AP developed IE within 
3 months of the procedure. This difference approached, but did not reach significance (p=0.08).  
 
This study is important. It again suggests that AP may be effective, but importantly confirms that, 
firstly AP is given inconsistently in the real world, and also that even if AP is effective it is unlikely to 
prevent large numbers of cases of IE. It is imperative that this study is replicated in other countries 
where such data is available.  
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What are the risks and costs of AP? 
 
In order to determine if AP should be recommended, it is not enough to simply assess whether or 
not AP can prevent cases of IE. It is also important to understand the potential adverse effects of 
giving AP. 
 
In the UK, we ƌĞǀŝĞǁĞĚ ?zĞůůŽǁĂƌĚ ?ĚĂƚĂƚŽĚĞƚĞƌŵŝŶĞƚŚĞƌĂƚĞŽĨĂĚǀĞƌƐĞ ǀĞŶƚƐĨƌŽŵƚŚĞƵƐĞŽĨ
amoxicillin and clindamycin as antibiotic prophylaxis.[48]  ?zĞůůŽǁ ĂƌĚƐ ? ĂƌĞ ĐŽŵƉůĞƚĞĚ ďǇ ŚĞĂůƚŚ
care professionals when adverse drug reactions are recorded, particularly after the introduction of a 
medication or if there has been a severe side effect. Over a 34-year period, there were no fatal 
reactions recorded with a single 3g oral dose of Amoxicillin and we could find no other reports of a 
fatal reaction in the world-wide literature either. For clindamycin given as a single 600mg dose 
orally, however, we identified 13 fatal reactions per million prescriptions. Most were due to 
Clostridium Difficile infection. If you believe that AP is effective, then it is easy to recommend 
amoxicillin as AP, as the risks of a fatal complication are extremely low. However, if a patient 
requires Clindamycin, then the decision to give AP is a little more nuanced, and is likely to require a 
more careful discussion with the patient.  
 
Combining data from the Lancet paper with the Yellow Card data enabled us to determine the cost-
effectiveness of AP.[49] We demonstrated that for patients at high-risk, AP would only have to 
prevent 3 cases every 2 years to be cost effective.  
 
The impact of AP on antibiotic resistance has not been formally assessed, and is an important 
consideration. As a community, we have a duty to minimise the prescription of antibiotics wherever 
possible. However, antibiotic resistance is believed to be encouraged when repeated courses of 
antibiotics at inadequate doses are given and is minimised by infrequent doses of antibiotics at high 
doses  ? as is the case for AP.[50] 
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Conclusions 
 
It remains unclear as to whether AP is effective. It is a subject which divides clinicians. A quote by 
Stuart Chase, an American economist, is ĂƉƚ ?  ?For those who believe, no proof is necessary. For 
ƚŚŽƐĞǁŚŽĚŽŶ ?ƚďĞůŝĞǀĞ ?ŶŽƉƌŽŽĨŝƐƉŽƐƐŝďůĞ ? ?  
 
There are no adequately powered randomised controlled clinical trials (RCTs) to help inform decision 
making in this field, and due to the rarity of the disease, there may never be. Therefore, a different 
approach is required, as elegantly discussed by Thomas Freiden in an article in the New England 
Journal of Medicine.[51] 
 
What is required is a synthesis of the evidence that does exist, followed by an honest balancing of 
the risks and benefits. We believe that when the evidence is taken as a whole it is impossible to 
exclude the possibility that AP does have an impact, albeit small. Furthermore, AP, particularly 
amoxicillin appears safe. Because IE is a devastating illness, very few cases have to be prevented to 
make it cost effective. There are clearly concerns about the promotion of antibiotic resistance and 
the overall costs of healthcare, but AP is cheap and the recommended dosing regimens are likely to 
minimise the development of antibiotic resistance.  
 
The concept of marginal gains has become important in many fields in recent years, particular in 
sports such as cycling. It seems likely that a similar strategy is required to reduce the burden of IE 
and to improve outcomes. We believe, when all of the evidence is considered, that AP is just one 
such  ?ŵĂƌŐŝŶĂů ŐĂŝŶ ? ŝŶ ƚŚĞ ŽŶŐŽŝŶŐbattle against IE, and that the benefits outweigh the risks, 
particularly for the use of AP in those at high-risk of IE, and possibly for those at moderate-risk, 
although we accept that definitive evidence is lacking.  
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Table 1 
 
Codes used to identify cases of infective endocarditis 
 
Studies Year P +/- S ICD-9 ICD-10 
421.0 421.1 421.9 424.9 112.81 036.42 098.84 115.04 115.14 115.94 I33.0 I33.9 I38 
Bikdeli 2013 P+S X X X X          
Pant 2015 P+S X X X           
DeSimone 2015 P X             
Mackie 2016 P X X X        X X  
Toyoda 2017 P+S X X X X X X X X X X    
Dayer 2015 P           X   
Keller 2016 P+S           X   
Van den Brink 2016 N/A ICD-9/10 codes not used; unique code in database 
 
P  ? Code searched for in primary position only; P+S  ? Codes searched for in any position 
 
 
Table 2 
 
Codes used to identify oral viridans group Streptococci (OVGS) 
 
 
 
 
 
 
 
 
 
* Positive predictive value for OVGS: 84% (68-100%) 
 
 
 
Studies Year ICD-9 ICD-10 
0380 0382 0410 04100 04101 04102 04103 04104 04105 04109 B95.0 B95.1 B95.2 B95.3 B95.4 B95.5 A40.8 A40.9 A49.1 
Bikdeli 2013 None 
Pant 2015 X X X X X X X X X X          
DeSimone 2015    X      X          
Mackie 2016 X   X      X     X X X X X 
Toyoda* 2017    X      X          
Dayer 2015 None 
Keller 2016           X X X X X X    
Van den Brink 2016 Subset of patients from 3 general hospitals with IE had their case notes reviewed directly; no population sample 
Tables
